Kalei­do sets terms for $100M IPO; Mallinck­rodt touts pos­i­tive PhI­II GVHD da­ta, cuts tri­al short

→ Mi­cro­bio­me drug de­vel­op­er Kalei­do Bio­sciences set the terms for its IPO on Tues­day, fol­low­ing in the foot­steps of Gos­samer Bio, Har­poon Ther­a­peu­tics and Stealth Bio which went pub­lic this year. The Lex­ing­ton, MA-based com­pa­ny, which plans to list un­der the sym­bol $KL­DO, is of­fer­ing rough­ly 4.8 mil­lion shares at price range of $20 – $22 to raise about $100 mil­lion, ac­cord­ing to an SEC fil­ing. Kalei­do was launched in 2015 out of Flag­ship Labs with a cat­a­logue of mi­cro­bio­me meta­bol­ic ther­a­pies that has since ex­pand­ed to over 1,000 can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER